TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07856004: A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Tacabrutideg in Participants With Moderate and Severe Hepatic Impairment

Sponsor: BeOne Medicines · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 24 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,131,408

Rescue Site Savings

+$2,731,696

Unlock Full NCT07856004 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07856004 Rescue Dossier →